Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $190.00 to $200.00. HC ...

Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Thursday, February 20th. HC Wainwright analyst R ...

Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session.

Below is Validea's guru fundamental report for AXSOME THERAPEUTICS INC (AXSM). Of the 22 guru strategies we follow, AXSM rates highest using our Value Investor model based on the published ...

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago. These figures ...

AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of -$0.96 per share, beating estimates of -$1. ...

Nick Pizzie, the Chief Financial Officer of $AXSM, sold 3,000 shares of the company on 02-14-2025 for an estimated $393,210. We received data on the trade from a ...